ISSN 3080-7670(Print)
ISSN 3080-7689(Online)
往期阅览
版权信息

ISSN 3080-7670(Print)
ISSN 3080-7689(Online)
CODEN:ZYYYBQ
(国际标准连续出版物标识符·
全球唯一标识符)
分配机构:美国化学文摘社(CAS)

编委会
主编
陈相宇
同行评议专家
安国尧/甘肃省中医院
副主编
陈金龙/中国新时代控股集团有限公司
刘磊/北京百川健康科学研究院
张丛雅/李桂玉/陈一健
刘海丽/马元昊/蔡伟茶
周盈丰/陈刚/杜英杰
(以上排名不分先后顺序)
编委
马国立/河北省第一荣军优抚医院
编委会助理
张悦
期刊主页
在线投稿
申请编委/副主编/同行评议专家
索引/检索/存档
DOI
ICI World of Journals
哥白尼索引期刊数据库(波兰)

EuroPub
欧洲学术出版中心数据库(英国)

Open Access Library(OALib)
开放存取资源图书馆

ESJI欧亚科学期刊索引(哈萨克斯坦)
Sci Online
Baidu Baike
Editing and Publishing
Quest Press Limited
Address
7th Floor,D, No.19,Palawak
Lane, Macau
Telephone
+853 6881 9699
Email
QuestPress@hotmail.com
Web site
http://zyyyj.scionline2025.com/

 

  首页 -> 往期阅览-> 2025年
《中医药研究与应用》( ISSN3080-7670、EISSN3080-7689 ) 发布者:Quest Press 发布日期:2025/10/9
10.12479/questpress-zyyyjyyy.20250102 Open Access 下载2 浏览39

 

海马多鞭丸治疗脾肾阳虚型多囊卵巢综合征的临床疗效观察报告

雷天翔   雷启峰   雷启发
山东省临沂市兰陵县男女不孕不育研究所,山东临沂,277700
摘要:目的 探讨脾肾阳虚型多囊卵巢综合征(PCOS)予以海马多鞭丸的临床疗效。方法 研究对象均选自山东省临沂市兰陵县男女不孕不育研究所,随机数字表法抽取200 例多囊卵巢综合征(脾肾阳虚型)患者临床资料,入选时间均在2023.5~2024.5 期间,分组以右归丸合归脾汤加减治疗的100 例,命名对照组,采用海马多鞭丸治疗的100 例,命名实验组。组间对比临床疗效。结果 组间总有效率比较,实验组、对照组各为75.00%(75/100)vs 51.00%(51/100),实验组高于对照组(p<0.05);治疗前,两组在性激素各项指标对比不存在统计学意义(p>0.05),治疗后实验组的各项指标经评定改善效果更明显,组间相比差异显著(p<0.05)。结论 海马多鞭丸在治疗脾肾阳虚型多囊卵巢综合征疗效显著,有效改善卵巢功能,调节内分泌系统和机体代谢的功能,在临床有推广前景。
关健词:海马多鞭丸;脾肾阳虚;多囊卵巢综合征;疗效;性激素
 
Clinical Efficacy Observation Report of Haima Duobian Pills for Polycystic Ovary Syndrome with Spleen-Kidney Yang Deficiency
Tianxiang Lei   Qifeng Lei   Qifa Lei
Infertility Research Institute of Lanling County, Linyi, Shandong 277700, China
Abstract:Objective To explore the clinical efficacy of Haima Duobian Pills in polycystic ovary syndrome (PCOS) with deficiency of Yang in the spleen and kidney. Methods The research subjects were all selected from the Male and Female Infertility Research Institute of Lanling County, Linyi City, Shandong Province. Clinical data of 200 patients with polycystic ovary syndrome(spleen and Kidney Yang deficiency type) were randomly selected by the random number table method. The inclusion time was from May 2022 to May 2022. 100 cases were grouped and treated with modified Yoului Pills and Guipi Decoction, and the control group was named. One hundred cases treated with Haima Duobian Pills were named the experimental group. The clinical efficacy was compared between groups. Results The comparison of the total effective rate between groups showed that the experimental group and the control group were 75.00% (75/100) vs 51.00% (51/100), and the experimental group was higher than the control group (p<0.05). Before treatment, there was no statistical significance in the comparison of various sex hormone indicators between the two groups (p>0.05). After treatment, the improvement effect of various indicators in the experimental group was evaluated to be more obvious, and the difference between the groups was significant (p<0.05). Conclusion Haima Duobian Pills have a remarkable therapeutic effect on polycystic ovary syndrome of spleen and kidney Yang deficiency type. They can effectively improve ovarian function, regulate the endocrine system and the body's metabolic function, and have a promising promotion prospect in clinical practice.
Keywords:Haima Duobian Pills; Spleen-Kidney Yang Deficiency; Polycystic Ovary Syndrome (PCOS); Efficacy; Sex Hormones
 
 
 
  Peer Review
同行评审
Editorial Services
编辑服务
Research Ethics Policy
研究伦理政策
Contributorship & Authorship
贡献者与署名
About Quest Press / Macau Sino Int. Med. Press
关于 Quest Press 与 Macau Sino Int. Med. Press
  Global Indexing
全球索引
Copyright Licensing
版权许可
Data Sharing Policy
数据共享政策
Appeal/Correction/Retraction
申诉/更正/撤回
  Online Submission
线上投稿
To the Librarian
致图书馆员
Open Access Statement
开放获取声明
Misconduct Handling Policy
处理不端行为政策
  Content Licensing
内容许可
Guidelines for Reviewers
审稿人指南
Quality Control Mechanism
质量把控机制
Academic Misconduct Screening Policy
学术不端筛查政策
  Advertising Policy
广告政策
Article Processing Charge (APC)
文章处理费
Publication Ethics Policy
出版伦理政策
Call for Editorial Board Members/Associate Editors/Peer Reviewers/Editors-in-Chief
诚邀编委、副主编、同行评审专家及主编